Loading stock data…
MDWD
$14.30+0.09 (+0.63%)
After Hours$14.30+0.00 (+0.00%)· Last close Jun 9
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MediWound Ltd. in the Healthcare sector is trading at $14.30 with a market capitalization of $176M. Wall Street consensus targets $30.17 (6 analysts), implying a +111.0% move over the next 12 months. The stock is currently near its 52-week low of $13.54, remaining 17.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +111.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 27) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$14.30
Potential Downside
0%
Whystock Fair Value$14.30
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Mean target$30.17+111.0%
Range$22.00 – $36.00
Fundamentals
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The compan...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$176.46M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.22
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-63.02%
Volume
Today's trading volume
91,523
Recent News
Will MediWound (NASDAQ:MDWD) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
MediWound Ltd (MDWD) Q1 2026 Earnings Call Highlights: Strategic Collaborations and Revenue ...
MediWound Ltd (MDWD) advances its ESCAREX program and secures a major BARDA contract, despite facing revenue declines and increased R&D expenses.
MediWound (MDWD) Q1 2026 Earnings Transcript
Ofer Gonen: Thank you, Dan, and good morning, everyone. While the timeline for EscharEx Phase III VALUE study has shifted by 1 quarter, the underlying momentum behind the program continues to strengthen. During this quarter, we expanded our chronic wound collaboration network, generated additional clinical and scientific validation for both EscharEx and NexoBrid and continue to see strong engagement from strategic collaborators and the broader wound care community.
MediWound Q1 Earnings Call Highlights
MediWound (NASDAQ:MDWD) reported a wider first-quarter loss and lower revenue compared with the prior-year period, while management reaffirmed its 2026 revenue outlook and said it continued to advance its EscharEx and NexoBrid programs. On the company’s earnings call, Chief Executive Officer Ofer G
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
MediWound (MDWD) delivered earnings and revenue surprises of +64.79% and -56.10%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?